FDA — authorised 26 March 2019
- Application: NDA209884
- Marketing authorisation holder: NOVARTIS
- Local brand name: MAYZENT
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Mayzent in United States
FDA authorised Mayzent on 26 March 2019
Marketing authorisation
Mayzent in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Mayzent approved in United States?
Yes. FDA authorised it on 26 March 2019.
Who is the marketing authorisation holder for Mayzent in United States?
NOVARTIS holds the US marketing authorisation.